Sunitinib As First-Line Treatment For Metastatic Renal Cell Carcinoma (mRCC)

April 13th, 2008 | Category: Cancer

UroToday.com - Updated results and analysis of prognostic factors from a phase III randomized trial.Sunitinib malate has demonstrated statistically superior progression-free survival (PFS) and objective response rate (ORR) compared with IFN-alfa (IFN-α) in

an universal, randomized phase III trial of first-line therapy in patients (pts) with metastatic renal cell carcinoma (mRCC).

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Safety And Efficacy Of Sunitinib In An Expanded-Access Trial Of Metastatic Renal Cell Carcinoma (mRCC)
  • Pfizer Presents Overall Survival input For Sutent™ Versus Interferon-Alfa - First Treatment To Demonstrate Overall Survival Greater Than 2 Years
  • A New Treatment Option For Patients With Renal Cancer
  • Management Guidelines For Patients On Sunitinib
  • Patients Given Sunitinib Need Close Monitoring For Cardiac Problems

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.